David Shook, MD, has been promoted to chief medical officer for Nkarta, a clinical-stage biotechnology company that develops natural killer cell therapy for cancer.
Dr. Shook has been with Nkarta since 2020 as a medical director and was appointed vice president of clinical affairs in May 2022, according to LinkedIn. He also practices as a pediatric oncologist and transplant physician.
Prior to joining Nkarta, Dr. Shook was a fellow, fellowship director and faculty member at St. Jude's Research Hospital in Memphis, Tenn., according to a Jan. 9 release announcing his promotion.
Dr. Shook has also developed and led a variety of first-in-human cell therapy clinical trials, including one focusing on the use of CD19 CAR-NK cells. He has also conducted research with Dario Campana, MD, PhD, Nkarta's scientific founder.